TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07310173: Phase IIb, Randomized, Active-Controlled, Parallel-Group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AST-3424 in Patients With AKR1C3-High Expressing Advanced Hepatocellular Carcinoma Who Progresse

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 75 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07310173 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07310173 Rescue Dossier →